Cheshire, UK -- (MARKET WIRE) -- December 28, 2006 --

                        Protherics PLC

               Total Voting Rights and Share Capital

London, UK; Brentwood, TN; 28 December 2006 - In conformity with the
Transparency Directive's transitional provision 6, Protherics PLC 
("Protherics"), the international biopharmaceutical company 
focused on critical care and cancer, is required to notify the 
market of the following:

Protherics' issued share capital consists of 261,489,793 ordinary shares with a
nominal value of 2 pence each, with voting rights. Protherics does not hold any
ordinary shares in Treasury.

Therefore, the total number of voting rights in Protherics is 261,489,793.

The above figure of 261,489,793 shares may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in,
Protherics under the Financial Service Authority's Disclosure and Transparency


For further information please contact:

Nick Staples, Director of Corporate Affairs         +44 (0) 7919  480510
Julie Vickers, Company Secretary                    +44 (0)1928 518010

Financial Dynamics - press enquiries
London: Ben Atwell, David Yates                     +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt             +1 212 850 5600

Or visit

                      This information is provided by RNS
            The company news service from the London Stock Exchange